HER2-TARGETED THERAPIES
Long-Term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer
This cross-sectional case-control study of patients with non-metastatic ERBB2-positve breast cancer who had undergone trastuzumab-based therapy demonstrated that resting mean left ventricular function was significantly lower among patients who had experienced cardiotoxicity during the trastuzumab-based treatment (56.9%) versus those who did not (62.4%), and compared to healthy controls (65.3%), in addition to other findings.
JAMA Cardiology
